Home Contact Sitemap

PedAM

Pediatric Disease Annotations & Medicines




Disease neuropathy
Phenotype C0009402|colorectal cancer
Sentences 10
PubMedID- 21444285 Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
PubMedID- 22496202 The present study investigated the occurrence of subclinical peripheral neuropathy in patients with colorectal cancer before the initiation of chemotherapy.
PubMedID- 22865779 Background: to report our prospective experience on the incidence and pattern of oxaliplatin (oxa)-induced peripheral neuropathy (oxa-ipn) in patients with colorectal cancer (crc) treated with either folfox-4 or xeloda + oxaliplatin (xelox).
PubMedID- 25713534 (2013) evaluated the efficacy of goshajinkigan for oxaliplatin-induced neuropathy in patients with colorectal cancer and demonstrated that goshajinkigan prevented exacerbation of neuropathy.
PubMedID- 25183707 A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy.
PubMedID- 24122404 A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer.
PubMedID- 25627820 We therefore conducted a multicenter randomized phase iii trial to compare fluorouracil, leucovorin, and oxaliplatin (mfolfox6) with and without goshajinkigan (gjg), a traditional japanese herbal medicine (kampo), to determine gjg's potential for reducing peripheral neuropathy in patients with colorectal cancer.
PubMedID- 22154408 Temporary interruption of oxaliplatin before limiting neurotoxicity develops during therapy is a potential approach to avoid the problem of oxaliplatin-associated neuropathy in patients with metastatic colorectal cancer.
PubMedID- 25417732 Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration.
PubMedID- 21814779 Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study.

Page: 1